Unique ID issued by UMIN | UMIN000010543 |
---|---|
Receipt number | R000012329 |
Scientific Title | Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test |
Date of disclosure of the study information | 2013/04/22 |
Last modified on | 2020/10/29 13:37:37 |
Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test
Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test
Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test
Comparison of metformin and vildagliptin in type 2 diabetes assessed by meal tolerance test
Japan |
type 2 diabetes
Endocrinology and Metabolism |
Others
NO
To compare metformin and vildagliptin for efficacy in type 2 diabetes
Safety,Efficacy
Comparison of glucose variability between two treatments by Meal Tolerance Test
Comparison of serum C-peptide and glucagon levels between two treatments
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Hospitalized patients with type 2 diabetes under insulin therapy or oral diabetic agents treatment will be enrolled. Insulin secretion will be evaluated by glucagon test prior to the treatments for this study to exclude the subjects without enough capacity of insulin secretion (deltaCPR <1.0ng/ml). After fasting blood glucose is controlled to the range from 80mg/dl to 130mg/dl (during pre observation period), either metformin (1000mg/day) or vildagliptin (100mg/day) will be administered to each patient for 3 days followed by MTT (First period).Then, the drug will be switched to another one for next 3 days followed by MTT (Second period). Finally, the combination of two drugs will be administered for last three days followed by MTT (Third period)
metformin 1000mg/day->vildagliptin 100mg/day
vildagliptin 100mg/day->metformin 1000mg/day
20 | years-old | <= |
75 | years-old | > |
Male and Female
Patients with type 2 diabetes who meet the following conditions:
(1)Age: younger than 75 years old, elder than 20 years old
(2)recent HbA1c : less than 12.0%
Patients who falls under any of the following conditions shall be excluded:
(1)Type 1 diabetes or type 2 diabetes with insulin-dependent condition
(2)severe renal and liver dysfunction
(3)unstable pre or proliferative diabetic retinopathy, severe neuropathy
(4)past history of the gastrointestinal tract or pancreas operation
(5)administered steroid drugs
(6)severe infection
(7)pregnant or planned pregnant in the near future
(8)ineligible for some other medical reasons judged by the investigator
30
1st name | Akira |
Middle name | |
Last name | Kawashima |
Naga Municipal Hospital
Department of Internal Medicine
6496414
1282 Uchita, Kinokawa City, 1282 Uchita, Kinokawa City, Wakayama 649-6414, Japan
0736-77-2019
soumu@nagahp.jp
1st name | Tetsushi |
Middle name | |
Last name | Nasu |
Naga Municipal Hospital
Department of Internal Medicine
649-6414
1282 Uchita, Kinokawa City, Wakayama 649-6414, Japan
0736772019
soumu@nagahp.jp
Naga Municipal Hospital
None
Self funding
Naga Municipal Hospital
1282 Uchita, Kinokawa City, Wakayama 649-6414, Japan
0736772019
soumu@nagahp.jp
NO
公立那賀病院 内科 Department of Internal Medicine, Naga Municipal Hospital
2013 | Year | 04 | Month | 22 | Day |
Unpublished
Terminated
2013 | Year | 04 | Month | 16 | Day |
2013 | Year | 04 | Month | 16 | Day |
2013 | Year | 04 | Month | 22 | Day |
2013 | Year | 07 | Month | 31 | Day |
2013 | Year | 04 | Month | 19 | Day |
2020 | Year | 10 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012329